高通量测序平行检测高级别浆液性卵巢癌胚系与体细胞BRCA1/2变异
该全国回顾性审计分析了2015年2月至2021年2月期间转诊至All Wales Medical Genomics Service的844例高级别浆液性卵巢/输卵管/腹膜癌患者,采用NGS进行胚系和/或肿瘤BRCA1/2检测。总体致病性变异检出率为11.6%,胚系检出率为9.2%(73/791)。在169例同时接受肿瘤和胚系平行检测的患者中,总体检出率为14.8%,其中体细胞致病性变异占6.5%(11/169)。结论认为平行胚系和肿瘤检测可最大化致病性变异检出。
要点
- 高级别浆液性卵巢癌患者中BRCA1/2总体致病性变异检出率为11.6%。
- 平行胚系与肿瘤检测可发现单独肿瘤检测漏掉的BRCA1剂量变异。
- 平行检测队列中体细胞致病性变异检出率为6.5%。
核心结论
- 平行胚系和肿瘤BRCA1/2检测可最大化高级别浆液性卵巢癌患者的致病性变异检出。
研究设计与样本
- 全国回顾性审计,纳入2015年2月至2021年2月转诊至AWMGS的844例高级别浆液性卵巢/输卵管/腹膜癌患者,分析NGS胚系和/或肿瘤检测数据。
主要发现
- 844例患者总体胚系/体细胞致病性变异检出率为11.6%。
- 胚系致病性变异检出率为9.2%(73/791)。
- 169例接受平行肿瘤和胚系检测的患者总体检出率为14.8%,其中体细胞致病性变异占6.5%(11/169)。
- 胚系筛查发现2例BRCA1剂量变异,占致病性变异患者的2.0%(2/98),单独肿瘤检测会漏检。
临床怎么用
- 对高级别浆液性卵巢癌患者应同时进行胚系和肿瘤BRCA1/2检测以最大化变异检出。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine the frequency of germline and somatic pathogenic BRCA1 and BRCA2 variants in patients with high-grade serous ovarian cancer tested by next-generation sequencing (NGS), with the aim of defining the best strategy to be implemented in future routine testing. DESIGN: National retrospective audit. SETTING: The All Wales Medical Genomics Service (AWMGS). POPULATION: Patients with high-grade serous ovarian/fallopian tube/peritoneal cancer referred by oncologists to the AWMGS between February 2015 and February 2021 for germline and/or tumour testing of the BRCA1 and BRCA2 genes by NGS. METHODS: Analysis of NGS data from germline and/or tumour testing. MAIN OUTCOME MEASURES: Frequency of BRCA1 and BRCA2 pathogenic variants. RESULTS: The overall observed germline/somatic pathogenic variant detection rate was 11.6% in the 844 patients included in this study, with a 9.2% (73/791) germline pathogenic variant detection rate. Parallel tumour and germline testing was carried out for 169 patients and the overall pathogenic variant detection rate for this cohort was 14.8%, with 6.5% (11/169) shown to have a somatic pathogenic variant. Two BRCA1 dosage variants were found during germline screens, representing 2.0% (2/98) of patients with a pathogenic variant that would have been missed through tumour testing alone. CONCLUSIONS: Parallel germline and tumour BRCA1 and BRCA2 testing maximises the detection of pathogenic variants in patients with high-grade serous ovarian cancer. TWEETABLE ABSTRACT: Parallel germline and tumour testing maximises BRCA pathogenic variant detection in ovarian cancer.
引用
- Frugtniet B, Morgan S, Murray A, et al. The detection of germline and somatic BRCA1/2 genetic variants through parallel testing of patients with high-grade serous ovarian cancer: a national retrospective audit. BJOG. 2021. PMID: 34657373. doi:10.1111/1471-0528.16975
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。